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Objective: This study aimed to apply the previously validated severity index for rheumatoid arthritis (SIFRA) to
prevalent rheumatoid arthritis (RA) groups in Turkey and determine the effect of RA severity on health care costs
and biologic use.
Methods: This retrospective study used the Turkish national health insurance database MEDULA (June 1, 2009-
December 31, 2011). Prevalent RA patients were required to be age 18 to 99, have two RA diagnoses at least 60
days apart and be continuously enrolled 1 year prior to (baseline period) and post (follow-up period) index date,
which was the first RA claim during the identification period (June 1, 2010-December 31, 2010). SIFRA was
calculated for the baseline period. Total health care costs and biologic use were examined for the follow-up period.
The chi-square test was used to determine the association between SIFRA score terciles and outcomes. Generalized
linear models were applied to determine health care costs while multivariate logistic regression determined the
effect of SIFRA on outcome measures for biologic use.
Results: A total of 1,920 patients were identified. The mean SIFRA score was 14.21, and 7.05 (49.57%) of the mean
composed of clinical and functional status variables, followed by 6.32 (44.47%) for medications, 0.48 (3.40%) for
radiology and laboratory findings, and 0.32 (2.25%) for extra-articular manifestation. There was a significant variation in
scores across cities. After controlling for age, gender, region, and comorbidity index, patients in the high SIFRA tercile
were 5.16 times more likely to be prescribed biologics (p<0.001, confidence interval [CI]: 3.46-7.69), and incurred annual
health care costs that were €2,091 higher (p<0.001, CI: €1,557 - €2,625) than those in the low SIFRA score tercile.
Conclusion: RA severity varies throughout Turkey and is a significant determinant of health care costs and biologic
therapy use. Therefore, future comparative effectiveness studies should include the severity measure in their analysis.
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Rheumatoid arthritis (RA), a progressive and disabling
autoimmune disease, has significant economic implica-
tions for individual patients as well as a society as a
whole [1,2].
The worldwide prevalence of RA has been estimated
at 1%, but tends to be higher in elderly populations [3].
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in any medium, provided the original work is pat 2% for persons over the age of 60 [4,5]. There are ap-
proximately 3 million RA patients in Europe [6].
There is no curative treatment for RA and joint damage
is progressive. Treatment of the diseased joints aims to
slow the progression of joint damage and restore pain-free
function. Prior to the advent of biologic therapies, com-
monly used pharmacological treatments included non-
steroidal anti-inflammatory drugs (NSAIDs), and disease
modifying anti-rheumatic drugs (DMARDs), such as
methotrexate, injectable gold salts, sulfasalazine and
leflunomide [7]. The introduction of biologic treatment
has transformed the expectations of RA management.
These medications have proven effective in slowingOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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minimizing disease activity [8]. Although effective, bio-
logics are an extremely expensive form of therapy [9]. The
use of biologic agents among newly diagnosed RA patients
has increased markedly over time, rising from 3% in 1999
to 26% in 2006 [10]. Therefore, in the last decade, health
care costs and utilization of patients with RA have been
increasingly recognized.
Costs associated with RA have been estimated at $8.7
billion annually in the United States [11]. RA is respon-
sible for 250,000 hospitalizations and more than 9 mil-
lion physician visits per year [12,13]. Since RA patients
have a peak onset near age 40 and often live for more
than 30 years with joint issues that adversely affect their
function, there are significant indirect costs associated
with RA [14]. In Europe, 32% of the average annual RA
costs were associated with indirect costs [2]. In a recent
study, 71% of the overall RA-related costs in Turkey
were associated with indirect costs [15].
An increasing proportion of the aging population [16],
combined with effective but expensive RA treatment op-
tions, is resulting in the need for disease-specific tech-
niques to estimate costs. Although many observational
studies have attempted to estimate the burden of RA, a
key limitation is the lack of disease severity measures in
datasets [17-20].
This study used a previously validated claims-based se-
verity index for rheumatoid arthritis to estimate the dis-
tribution of disease severity across regions in Turkey
[21-23]. As a secondary objective, the association be-
tween disease severity and health care costs and
utilization was analyzed among patients diagnosed with
RA in Turkey. Finally, the study also examined the rela-
tionship between disease severity and biologics use.
Methods
A retrospective analysis was performed using medical
and pharmacy claims and eligibility data from the re-
search identified MEDULA dataset for diagnosed RAFigure 1 Study period.patients in Turkey. The MEDULA dataset encompasses
17,800 pharmacies, 5,600 general practitioners, 4,500
medical centers, 1,200 government hospitals and 338
private hospitals covering more than 80% of the Turkish
population.
All patients diagnosed with RA were identified using
the appropriate diagnosis codes from the International
Classification of Disease Tenth Revision Clinical Modifi-
cation (ICD-10-CM) for the identification period (June
1, 2010 - December 31, 2010; Figure 1). Patients were re-
quired to have two RA diagnoses at least 60 days apart.
The requirement of two visits and a period between
claims has been shown to increase the reliability of the
RA diagnosis [14]. The date of the first diagnosis claim
was designated as the index date. All patients were re-
quired to be at least age 18 years on the index date and
continuously enrolled in the health plan throughout the
1-year pre- (baseline) and 1-year post-index (follow-up)
periods. Since this study particularly focused on preva-
lent patients, an RA diagnosis during the baseline period
was required. All medical claims were compiled over the
study period for all remaining patients.
The severity index for rheumatoid arthritis (SIFRA)
score was derived for each patient. SIFRA is composed of
a set of 28 RA-related indicators from a study by Cabral et
al. [22]. These indicators were sub-grouped as clinical and
functional status, extra-articular manifestations, surgical
history and medications (Table 1). The strength of each
relationship was measured from 0=no relationship, to
6=perfect relationship and assessed by six board-certified,
clinically active rheumatologists according to the Delphi
panel method. The index was validated and applied to the
U.S. Department of Veteran Affairs, Veterans Health
Administration (VHA) data [21,23].
Demographic variables such as patient gender and age
were available in the data. Since Turkey is divided into
seven regions, flags were created according to patient re-
gion of residence. For each city, the proportion of patients
with the highest SIFRA tercile score was calculated. These
Table 1 SIFRA indicators
Rating 1
Radiology and Laboratory Findings Mean (Range)
Presence of RF Ever 2.7 (2–4)
Presence of HLA Subtype 3.0 (1–4)
C1-2 Subluxation 5.2 (5–6)
Presence of CCP Ever 3.0 (2–4)
Clinical and Functional Status Measures
Number of Rheumatologist Visits 3.2 (2–4)
Extra-articular Manifestations
Pulmonary Nodules 3.5 (3–5)
Subcutaneous Nodules 2.8 (2–4)
Vasculitis Ever 5.0 (4–6)
Felty's Syndrome Ever 5.0 (4–6)
Surgical History
Cervical Spine Fusion 5.5 (5–6)
Foot Joint Replacement 4.2 (2–6)
Total Hip Replacement 5.2 (4–6)
Total Knee Replacement 5.2 (4–6)
Elbow Replacement 5.3 (4–6)
Shoulder Replacement 5.5 (5–6)
Medications
Any Oral Glucocorticoid Use 2.8 (2–4)












TNF (ADA, ETN, IFX) 4.1
Non-TNF (ABA, RTX) 4.8
RF=rheumatoid factor; HLA=human leukocyte antigen; C1-2=cervical
spine 1-2; CCP=anti-cyclic citrullinated peptide; TNF=tumor necrosis
factor; ADA=adalimumab; ETN=etanercept; IFX=infliximab; ABA=abatacept;
RTX = rituximab.
Note: For new biologic therapies approved since the “Delphi panel”, average
scores were applied depending on class. For adalimumab, infliximab,
etanercept, average of TNF blockers, a rating of 4.1 was applied; for abatacept
and rituximab, average of non-TNF (4.8) was applied. Also medium and small
joint fusion (4.825) and large joint fusion (5.3) was applied.
Baser et al. Health Economics Review 2013, 3:5 Page 3 of 7
http://www.healtheconomicsreview.com/content/3/1/5proportions were ranked and presented using a Turkish
map to show RA severity distribution at the city level
(Figure 2).
In addition to SIFRA scores, comorbidity scores using
the Elixhauser index method [24] were also calculated.
The Elixhauser index is defined as the sum of a compre-
hensive set of 30 present comorbid conditions and has
been widely used to determine patient health status.
Three sets of outcomes were defined: a) total health care
costs; b) total health care utilization; and c) total medica-
tion use. Total health care costs were calculated for the
follow-up period as a sum of inpatient, outpatient, phar-
macy and copay amounts and adjusted to 2011 costs.
Hospitalization, outpatient visits, rehabilitation visits and
surgery rates were also estimated for the follow-up period.
In terms of medication use, rates of biologics use were cal-
culated for the follow-up period.
The association between SIFRA terciles and outcomes
were assessed using the Chi-square test.
In order to estimate the effect of the severity score on
health care costs, generalized linear models (GLMs)
were used [25]. Following the Park test, the Gamma dis-
tribution with log link was selected [26]. The logistic re-
gression model was used to determine binary outcomes.
All statistical analyses were conducted using SAS v.9.3
and STATA v.11 software.
Results
For the 1,920 RA patients identified, SIFRA scores
ranged between 0 and 69.40, with a mean value of 14.21,
and a standard deviation (STD) of 10.26. Mean SIFRA
scores, (Table 2) were 7.05 (49.57%), which composed of
clinical and functional status variables, followed by 6.32
(44.47%) for medications, 0.48 (3.40%) of radiology and
laboratory findings, 0.32 (2.25%) for extra-articular man-
ifestations (pulmonary nodules, subcutaneous nodules,
vasculitis ever, and Felty’s syndrome ever), and 0.04
(0.31%) for surgical history (cervical spine fusion, hand/
foot joint replacement, foot joint/ankle/wrist fusion and
total hip/knee/elbow/shoulder replacement).
Figure 2 shows the distribution of patients with the
highest tercile of SIFRA scores across cities. The top four
cities with the highest density of severe RA patients were
Bolu (84%), Kocaeli (63%), Antalya (59%) and Izmir (52%).
Total costs, as well as components of total health care
costs (copays, inpatient, outpatient, pharmacy costs) by
SIFRA score tercile are presented in Figure 3. Histograms
indicate that patients in the upper tercile of SIFRA in-
curred €1,851 higher health care costs, €1,647 higher
pharmacy costs, €116 higher outpatient costs, and €85
higher inpatient costs. The difference in copayments was
approximately €3.
Figure 4 presents the relationship between baseline
SIFRA scores and the use of biologic therapies in the
Figure 2 Rheumatoid arthritis severity distribution (by SIFRA terciles) across cities in Turkey.
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ation of biologic use in more severe patients. Roughly
one quarter (25.75%) of the patients in the upper tercile
of SIFRA were prescribed biologics, whereas only 5.6%
of patients in the lowest SIFRA tercile were prescribed
biologics in the follow-up period. (p<0.001)
Using multivariate analysis, the effect of SIFRA scores
on health care costs, hospitalization and biologics use
was estimated. After controlling for age, gender, region,
and comorbidities, patients in the high SIFRA tercile
were 5.16 times more likely to be prescribed biologics
(p<0.001, CI: 3.46-7.69) and incurred annual health care
costs that were €2,091 greater (p<0.001, CI: €1,557-
€2,625) than for those in the lower SIFRA tercile.
Discussion
Randomized clinical trials (RCT), although described as the
“gold standard” to estimate treatment effects, have limita-
tions. Small sample size, generalizability, trial costs and time
restrictions limit the applicability of RCTs [27]. Observa-
tional studies can support clinical trials by providing
real-world practice patterns across geographic regions,
hospitals, and patient subgroups. However, the main limita-
tion of observational studies is the lack of control forTable 2 SIFRA score distribution
Variable N Mean
SIFRA with Laboratory Data (SIFRA1) 1,920 14.21 (100%
Radiology & Laboratory Findings 1,920 0.48 (3.40%
Clinical & Functional Status 1,920 7.05 (49.57%
Extra-articular Manifestations 1,920 0.32 (2.25%
Surgical History 1,920 0.04 (0.31%
Medication 1,920 6.32 (44.47%
SIFRA=severity index for rheumatoid arthritis; Min=minimum; Max=maximum; STD=hidden bias. Hidden bias occurs when at least one variable
belonging to the estimation model is missing from the data
and, therefore, is not controlled for. When disease severity
is missing from the data, the term is left in the error terms
in risk-adjustment models, causing bias in the estimates.
Although there are advanced techniques to statistically
handle hidden bias, complex models often require add-
itional variables that are rarely available in datasets [28,29].
Due to the advancement in therapeutic options for RA
patients and the high cost required to utilize them, the
need for cost effective treatment methods is significant,
particularly in the expanding aging population. RA
expenditures are estimated at €9,946 in Belgium [18],
€5,029 in the Netherlands [17], €4,000 in France, and
€2,312 in Germany [16]. Overall, the estimated cost in
Europe was calculated at €2,835, excluding pharmacy
expenditures. Previous studies that attempted to esti-
mate the costs of RA in Turkey were based on expert re-
ports, local estimates and questionnaires. A recent study
by Malhan et al. [15] estimated total annual medical
costs per RA patient at €2,917. An earlier study, using
data collected from hospital bills, estimated the annual
cost to be €2,669. Other RA studies mostly pertained to
disease prevalence and epidemiology in Turkey.Min Max Median STD
) 0.00 69.40 12.10 10.26
) 0.00 6.00 0.00 1.15
) 0.00 54.40 3.20 8.50
) 0.00 10.00 0.00 1.21
) 0.00 10.03 0.00 0.50
) 0.00 19.30 6.60 3.65
standard deviation.
Figure 3 SIFRA scores and health care costs.
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estimates from these prior studies were interpreted with
caution. In some of the studies, severity was proxied
with comorbidity index values, which were not specific-
ally designed for RA. These indexes showed low correl-
ation with the severity of RA.Figure 4 Association between SIFRA Scores and biologic use.A recent publication attempted to create a claims based,
validated severity index for rheumatoid arthritis [23]. This
index correlated highly with a record-based index score
(RARBIS) and increased the prediction power of the
models. This research applied the severity index on health
care costs and utilization in patients with RA in Turkey,
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ation between RA severity and health care outcomes (such
as cost, utilization and biologic use) in Turkey.
Note that one of the indicators in severity index for
rheumatoid arthritis (SIFRA) are biological therapies. In
order to estimate the effect of RA severity on biologic
use, on needs to create this index using baseline use of
biological therapies. All of the indicators should be cal-
culated in the baseline to create the index otherwise one
might have endogeneity problem in estimating the
models. Thus, the estimators would be biased.
Although this study controlled for severity by using the
claims-based severity index for RA, there are other limita-
tions in this analysis, which are typical of any claims-
based data. Since claims data are collected for payment
rather than research purposes, the presence of diagnostic
codes on a medical claim does not necessarily prove exis-
tence of the actual disease. However, the probability that a
patient with RA diagnostic codes also has RA was
reported at 95%. Two RA diagnoses occurring at least
60 days apart were applied in order to mitigate the in-
correct coding and rule-out criteria. Diagnosis codes used
to define comorbidities have over 90% specificity.Conclusion
This paper applied the previously validated RA severity
scores for diagnosed patients in Turkey. According to se-
verity scores, the total medical costs of RA patients ranged
from €1,435 to €3,275. The use of biologics was positively
correlated with the severity score. Since statistically omit-
ting a variable that belongs in population models provides
biased and inconsistent estimates, any comparative effec-
tiveness studies in RA treatment should include severity
scores.Consent
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